DE69033863T2 - Verwendung von 5-methyl-1-phenyl-2-(1H)-pyridon zur Vorbeugung fibrotischer Schädigungen - Google Patents

Verwendung von 5-methyl-1-phenyl-2-(1H)-pyridon zur Vorbeugung fibrotischer Schädigungen

Info

Publication number
DE69033863T2
DE69033863T2 DE69033863T DE69033863T DE69033863T2 DE 69033863 T2 DE69033863 T2 DE 69033863T2 DE 69033863 T DE69033863 T DE 69033863T DE 69033863 T DE69033863 T DE 69033863T DE 69033863 T2 DE69033863 T2 DE 69033863T2
Authority
DE
Germany
Prior art keywords
pyridone
methyl
phenyl
fibrotic damage
prevent fibrotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69033863T
Other languages
English (en)
Other versions
DE69033863D1 (de
Inventor
Solmon B Margolin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Yamauchi Shitotomo
Margolin Solomon B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamauchi Shitotomo, Margolin Solomon B filed Critical Yamauchi Shitotomo
Application granted granted Critical
Publication of DE69033863D1 publication Critical patent/DE69033863D1/de
Publication of DE69033863T2 publication Critical patent/DE69033863T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69033863T 1989-02-15 1990-02-15 Verwendung von 5-methyl-1-phenyl-2-(1H)-pyridon zur Vorbeugung fibrotischer Schädigungen Expired - Lifetime DE69033863T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1035436A JPH02215719A (ja) 1989-02-15 1989-02-15 線維化病変組織の修復並びに線維化病変の阻止剤

Publications (2)

Publication Number Publication Date
DE69033863D1 DE69033863D1 (de) 2002-01-03
DE69033863T2 true DE69033863T2 (de) 2002-06-13

Family

ID=12441800

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69033863T Expired - Lifetime DE69033863T2 (de) 1989-02-15 1990-02-15 Verwendung von 5-methyl-1-phenyl-2-(1H)-pyridon zur Vorbeugung fibrotischer Schädigungen
DE69034143T Expired - Lifetime DE69034143T2 (de) 1989-02-15 1990-02-15 Zusammensetzung, welche 5-Methyl-1-phenyl-2-(1 H)-pyridone enthält, zur fixierung und Vermeidung von fibrotischen Schädigungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69034143T Expired - Lifetime DE69034143T2 (de) 1989-02-15 1990-02-15 Zusammensetzung, welche 5-Methyl-1-phenyl-2-(1 H)-pyridone enthält, zur fixierung und Vermeidung von fibrotischen Schädigungen

Country Status (9)

Country Link
EP (3) EP0458861B1 (de)
JP (1) JPH02215719A (de)
AT (1) ATE136215T1 (de)
AU (1) AU633541B2 (de)
CA (1) CA2010017C (de)
DE (2) DE69033863T2 (de)
DK (1) DK0458861T3 (de)
ES (2) ES2220612T3 (de)
WO (1) WO1990009176A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
JPH08510251A (ja) * 1993-05-07 1996-10-29 ビー マーゴリン、ソロモン 線維症の病変の修復と予防のための組成物および方法
EP0813409B1 (de) * 1995-03-03 2004-05-06 MARGOLIN, Solomon B. Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden
AU1226099A (en) * 1998-09-18 2000-04-10 Mepha Ag Topical formulation of alkyl-, phenyl-pyridone
US7867516B2 (en) 2001-01-29 2011-01-11 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
JP4542743B2 (ja) 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
TW200501952A (en) * 2003-02-21 2005-01-16 Shionogi & Co Pirfenidone gel formulations
WO2004073680A1 (ja) * 2003-02-21 2004-09-02 Shionogi & Co., Ltd. 液滴分散型軟膏剤
US7825133B2 (en) 2003-11-14 2010-11-02 Shanghai Genomics, Inc. Derivatives of pyridone and the use of them
CN1846699A (zh) * 2005-04-13 2006-10-18 中南大学湘雅医院 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
ATE533486T1 (de) 2006-06-15 2011-12-15 Shanghai Genomics Inc Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung
MX2007006347A (es) * 2007-05-29 2009-02-18 Cell Therapy And Technology S Nuevo uso de 5-metil-1-fenil-2-(1h)-piridona para el tratamiento y prevencion de cicatrices hipertroficas, y composicion conteniendo la misma.
NZ599643A (en) 2007-06-20 2013-11-29 Auspex Pharmaceuticals Inc Substituted N-aryl pyridinones as fibrotic inhibitors
CN101918364B (zh) * 2008-10-21 2013-02-13 史跃年 用于治疗高蛋白尿的药物组合物
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US7816383B1 (en) * 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
EP4059499A1 (de) * 2011-01-31 2022-09-21 Avalyn Pharma Inc. Aerosolförmige pirfenidon- und pyridonanalogverbindungen und verwendungen davon
US9018232B2 (en) 2011-03-08 2015-04-28 Auspex Pharmaceuticals, Inc. Substituted N-aryl pyridinones
JP5872564B2 (ja) * 2011-09-14 2016-03-01 塩野義製薬株式会社 吸入用医薬組成物
CA2872110C (en) 2012-07-18 2019-08-06 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
EP3083584B1 (de) * 2013-12-19 2018-02-21 Sunshine Lake Pharma Co., Ltd. Heterocyclische stickstoffderivate und deren anwendung in arzneimitteln zur behandlung von der gewebefibrose
EP3307714A1 (de) 2015-01-26 2018-04-18 Ulkar Kimya Sanayii Ve Ticaret A. S. Verbessertes verfahren für die synthese und reinigung von pirfenidon
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
CN109223723B (zh) * 2017-07-11 2021-08-27 南京华威医药科技集团有限公司 吡非尼酮片剂及其制备方法和用途
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
MX2020005775A (es) * 2020-07-13 2022-01-14 Centro De Retina Medica Y Quirurgica S C Uso farmaceutico de pirfenidona para la reduccion de fibrosis cardiaca en pacientes con cardiomiopatia y/o esteatosis cardiaca y/o covid-19.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6816241A (de) * 1967-12-01 1969-06-03
US3721676A (en) * 1969-11-12 1973-03-20 Merck & Co Inc Certain 3-amino-2(1h)pyridones
US3644626A (en) * 1969-11-25 1972-02-22 Merck & Co Inc Novel pyridones in compositions and methods for treating inflammation pain and fever
US3655897A (en) * 1971-01-25 1972-04-11 Merck & Co Inc Anti-inflammatory agents
US4042699A (en) * 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
CA1049411A (en) * 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US4052509A (en) * 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
ZA757570B (en) * 1974-12-09 1977-07-27 Affiliated Med Res A useful n-substituted pyridone
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤

Also Published As

Publication number Publication date
WO1990009176A1 (en) 1990-08-23
DE69034143T2 (de) 2005-06-30
ES2163389T3 (es) 2002-02-01
EP1138329B1 (de) 2004-06-02
JPH02215719A (ja) 1990-08-28
EP1138329A3 (de) 2002-04-17
AU4981290A (en) 1990-08-23
DE69034143D1 (de) 2004-07-08
CA2010017A1 (en) 1990-08-15
EP1138329A2 (de) 2001-10-04
DK0458861T3 (da) 1996-08-12
JPH0552814B2 (de) 1993-08-06
EP0383591B1 (de) 2001-11-21
EP1138329B8 (de) 2006-05-17
EP0458861B1 (de) 1996-04-03
EP0458861A4 (en) 1992-07-08
ES2220612T3 (es) 2004-12-16
AU633541B2 (en) 1993-02-04
EP0383591A2 (de) 1990-08-22
DE69033863D1 (de) 2002-01-03
ATE136215T1 (de) 1996-04-15
EP0383591A3 (de) 1992-01-15
EP0458861A1 (de) 1991-12-04
CA2010017C (en) 1995-09-05

Similar Documents

Publication Publication Date Title
DE69033863T2 (de) Verwendung von 5-methyl-1-phenyl-2-(1H)-pyridon zur Vorbeugung fibrotischer Schädigungen
DE69132006T2 (de) Thiazolederivate als inhibitoren von aktivem sauerstoff
NL930005I2 (nl) 17 Beta-gesubstitueerde-4-aza-5alfa-androstenonen en gebruik ervan als inhibitoren van 5alfa-reduct ase.
ES2095380T3 (es) Derivados de indano-2-carboxialquilo sustituidos en la posicion 2 utiles como inhibidores de la encefalinasa y la eca.
DE69115360D1 (de) Verfahren und Gerät zur Pflege der Aktivität einer Enzymelektrode
FI913142A (fi) Migraenfoerhindrande alkoxipyrimidinderivat.
DE68908242D1 (de) Verfahren zur verbesserung der wirksamkeit von insektentoxinen.
EP0273689A3 (en) Derivatives of n-(2-alkyl-3-mercapto-glutaryl) alpha-amino acids and their use as collagenase inhibitors
DE3676447D1 (de) Zusammensetzung und verfahren zur bestimmung der peroxidartigen aktivitaet des haemoglobins.
GR1001218B (el) Μεθοδος παρασκευης αλατων κεφαλοσπορινης και ενεσιμων συνθεσεων
DE3888953T2 (de) Verwendung von cellulase beim nassvermahlen.
AU642537B2 (en) 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
ZA838825B (en) 2-,3-,or 4-pyridinylmethylamino arylic acids as txa2 and lipoxygenase inhibitors
ATA225884A (de) Verwendung von substituierten glycinamiden als antidota in herbiziden mitteln und herbizide mittel
DE69307050D1 (de) Reihe von Elementen zum Gebrauch im belüfteten Fassadenbau
DE59303284D1 (de) Vorrichtung zur Schadensverhinderung an Gebäuden in Bereichen von Bodenbewegungen
ATA1096A (de) Verwendung von alkali- und/oder triethanolaminsalzen der alkanoylamidocarbonsäuren in der metallbearbeitung
ATA63587A (de) Mittel zur erdalkaliduengung von gehoelzen
ES292519Y (es) Nudo estructural para conformacion de entreplantas en almacenes y similares
DE69430190T2 (de) Hemmer der aktivität von endothelin
IT8847888A0 (it) Composizioni erbicide sinergiche erelativo impiego di applicazione
NO885665L (no) Fremgangsmaate til fremstilling av 2-(4-(2-(4-klor-benzamido)etyl)fenoksy)-2-metylpropionsyre og mellomprodukter foranvendelse i fremgangsmaaten.
ATE103937T1 (de) Verwendung von cellulase beim nassvermahlen.
ES292804Y (es) Estructuracion perfeccionada para frontis de armarios y muebles similares
BR6401935U (pt) Carrinho de chopp ambulantes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: KDL GMBH, ZUG, CH

Owner name: MARGOLIN, SOLOMON B., DALLAS, TEX., US

8327 Change in the person/name/address of the patent owner

Owner name: INTERMUNE, INC., BRISBANE, CALIF., US